Israeli Startup Develops AI-Driven GLP-1 Peptide Alternative

Israeli startup Lembas has launched GLP-1 Edge, an AI-powered bioactive peptide designed to stimulate the GLP-1 hormone for appetite regulation. This innovation aims to provide a cost-effective, side-effect-free alternative to existing medications like Ozempic, addressing a growing market need for weight management solutions. The company secured $3.6 million in pre-seed funding to advance commercialization and expand its AI discovery platform.

Original excerpt: Lembas, a startup born out of Tel Aviv, is betting on that with GLP-1 Edge…

Source: Green Queen